Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
| | |

Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease

On Sept. 15, 2025, Corstasis Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved ENBUMYST™…

Albert Einstein Cancer Center’s Liver Research Center became the first institute in the nation devoted to the study of liver disease and injury
| | | | | | |

Albert Einstein Cancer Center’s Liver Research Center became the first institute in the nation devoted to the study of liver disease and injury

In 1974, Albert Einstein Cancer Center’s Liver Research Center — now the interdisciplinary Marion Bessin Liver Research Center…